Ingenuity Systems Joins Biomarkers Consortium
Ingenuity Systems has joined the Biomarkers Consortium, a public-private endeavor aimed at developing, discovering, and qualifying new biomarkers for drug development, preventive medicine, and medical diagnostics.
The consortium was founded by the Foundation for the National Institutes of Health, the National Institutes of Health, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the Pharmaceutical Research and Manufacturers of America. It now comprises around 30 partners, including companies, patient advocacy organizations, government groups, and non-profits.
The consortium this summer launched a website that offers more information, accepts proposals for projects, and offers information on funding opportunities.
Ingenuity makes pathway analysis and knowledge-base software that helps researchers explore, analyze, and interpret scientific literature and data.
University of British Columbia Selects InforSense GenSense for Bioinformatics
InforSense said this week that the University of British Columbia's James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, based at St. Paul's Hospital in Vancouver, BC, has selected InforSense GenSense to support its genetic research programs into heart, lung, and vascular systems.
"The volume of data being generated by the latest genotyping technologies is very large and growing exponentially, and we require a tool that scales to automatically check and analyze these large data sets,” said Scott Tebbutt, principal investigator and assistant professor at the James Hogg iCAPTURE Centre, in a prepared statement.
"We are delighted to work with UBC's iCAPTURE Centre to leverage GenSense within their research programs,” said Joseph Donahue, senior vice president at InforSense. "GenSense provides comprehensive functionality out-of-the-box, and because it is based on the InforSense platform, customers can easily modify their workflows to meet new requirements in this emerging and fast-paced research area.”
The James Hogg iCAPTURE Centre – which stands for Imaging, Cell Analysis, and Phenotyping Toward Understanding Responsive, Reparative, Remodelling, and Recombinant Events – at St. Paul's Hospital is a UBC Senate-approved research center supported by the faculty of medicine of UBC and Providence Health Care.
IO Informatics and Partek to Partner Again, Offer Data Integration and Analysis
IO Informatics and Partek have announced the renewal of their partnership, which began in 2005. Together, the two companies will work toward providing an environment for data integration and analysis.
Partek provides statistical analysis and interactive data visualization software for the scientific researchers, while IO Informatics provides its Sentient software suites to the biotech, Pharma, and medical industries.
IOI will use its suite of data integration applications for life sciences in the partnership.
DJ Meyer, vice president of Partek, said in a company missive that, “We’ve appreciated our partnership with IOI as they have continued to evolve their data integration environment for life science researchers, and we are happy to be an active partner with them as their company continues to expand, especially in the area of translational medicine and biomarker research.”
The renewed partnership will enable existing customers and other users to open information from the Sentient suite within the Partek GS, perform analysis, and bring the results back into the knowledge-building environment of Sentient.
Biomax Informatics Acquires Data Mining Business from Eudaptics Software
Biomax Informatics has acquired the Viscovery software business of the Austrian data mining specialist Eudaptics Software. Terms of the agreement were not disclosed.
Biomax, based in Martinsried, Germany, sells knowledge management software, and said the Viscovery product line provides "a visual approach to data exploration,” according to a company statement.
The company said that the combination of its BioXM platform with Viscovery will be particularly useful "for areas such as biomarker identification, toxicology, and clinical research."
The transaction is expected to expand both companies’ products into new markets.
Viscovery will continue to develop its data-mining software, and said updates and new offerings will be made available to existing and new customers.
Gene Logic and FDA to Explore Genomic Data Quality for Safety, Effectiveness
Gene Logic announced that it is has entered into a collaboration with the US Food and Drug Administration to share quality control methods and metrics that could be of use in understanding genomic data sent as part of the regulatory process.
The collaboration stems from the FDA’s Critical Path Initiative, an effort to bolster the use of new scientific and technical methods such as computer-based predictive models and biomarkers for safety and effectiveness. The initiative is designed to improve the predictability and efficiency of drug development from laboratory concept to commercially-approved medicines.
In a prepared statement, Gene Logic’s Donna Mendrick, a scientific fellow and VP of toxicogenomics for the company, said “Industry and FDA consensus is that biomarkers are valuable tools for assessing the safety and efficacy of drug candidates. This collaboration between Gene Logic and the FDA is a step on the path to achieving a common understanding of key microarray QC procedures that may lead to the development of preliminary microarray data standards for the submission of microarray data to the FDA.”
An FDA official was quoted in the same statement as saying that there are currently no industry standards in place for microarray data submission to the FDA, “and projects focused on understanding the QC issues will help drive the development of baseline standards for the submission of microarray data to the FDA in the future.”